West Pharma (WST) Tops Q2 EPS by 3c; Raises Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
West Announces Second Quarter 2016 Results
July 28, 2016 7:01 AM EDTEXTON, Pa., July 28, 2016 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the second quarter 2016 and updated financial guidance for the full-year 2016.Â
Second Quarter 2016 Highlights
Reported net sales of $388.0 million grew 7.9% over the prior-year quarter. Net sales at constant currency grew by 8.2%. Second quarter 2016 reported diluted EPS was $0.60 as compared to $0.38 in the prior-year quarter. Excluding restructuring and retirement charges from both periods, adjusted diluted EPS was... More